Indication
Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).
Loading your page…
Loading your page…
Fabry Disease
Marketing Authorisation Holder: Chiesi Farmaceutici S.p.A
EMA Authorisation: 04/05/2023
INN: pegunigalsidase alfa
AI Drug & Interaction Analysis
Free account required
Ask Osler about Elfabrio: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.